Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

St. Joseph’s Companion Aspirin

This article was originally published in The Tan Sheet

Executive Summary

McNeil Consumer & Specialty Pharmaceuticals introduces specially packaged St. Joseph's aspirin for consumers to take in the event of a suspected heart attack, the firm announces Aug. 23. Companion Aspirin, which began shipping in July, includes three individual packets, each containing two chewable tablets of aspirin 81 mg. Each individual packet provides the "emergency" dose recommended at onset of heart attack symptoms in an easy-to-open pouch and will retail for $1.00, McNeil notes. FDA approved modified labeling for aspirin in 1998, allowing language recommending aspirin use during suspected acute myocardial infarction (1"The Tan Sheet" Oct. 26, 1998, p. 4)...

You may also be interested in...



Aspirin Professional Indications Add Use During Acute MI In FDA Final Rule

FDA's final rule on professional labeling for aspirin includes an indication for aspirin use during suspected acute myocardial infarction as soon as a heart attack is suspected, as directed by health care personnel.

Roche/Genentech Keeps Commitment To External Cancer Innovation

Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.

US FDA Eases Changes For Certain Sterile Injectable Container Closure Materials

To mitigate pandemic disruption of component supply chains, the US FDA said it will downgrade some post-approval change categories for sterile drug container closure systems. The downgrade will cover drugs in shortage and those used to treat COVID-19.

Topics

UsernamePublicRestriction

Register

OM009724

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel